AAREY DRUGS & PHARMACEUTICALS
|
AAREY DRUGS & PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 1.41 | 1.67 | 1.49 | 2.58 | 2.79 |
| CEPS(Rs) | 2.10 | 2.27 | 2.11 | 3.37 | 3.18 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 47.78 | 46.45 | 45.34 | 43.85 | 41.29 |
| Tax Rate(%) | 34.05 | 12.34 | 37.25 | 34.69 | 21.53 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 0.61 | 1.63 | 1.84 | 2.31 | 1.33 |
| EBIT Margin(%) | 2.27 | 2.44 | 2.12 | 2.45 | 3.08 |
| Pre Tax Margin(%) | 1.29 | 1.34 | 1.43 | 2.04 | 2.38 |
| PAT Margin (%) | 0.85 | 1.18 | 0.90 | 1.33 | 1.87 |
| Cash Profit Margin (%) | 1.26 | 1.60 | 1.28 | 1.73 | 2.13 |
| Performance Ratios | |||||
| ROA(%) | 1.36 | 1.58 | 1.41 | 2.74 | 3.05 |
| ROE(%) | 3.02 | 3.82 | 3.33 | 6.31 | 6.98 |
| ROCE(%) | 6.38 | 6.09 | 6.28 | 9.87 | 9.46 |
| Asset Turnover(x) | 1.60 | 1.34 | 1.56 | 2.06 | 1.63 |
| Sales/Fixed Asset(x) | 12.87 | 11.86 | 12.83 | 15.88 | 12.23 |
| Working Capital/Sales(x) | 4.07 | 3.43 | 4.09 | 5.35 | 3.98 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.08 | 0.08 | 0.08 | 0.06 | 0.08 |
| Receivable days | 122.43 | 171.77 | 142.04 | 110.48 | 135.22 |
| Inventory Days | 30.87 | 29.14 | 18.51 | 11.91 | 18.57 |
| Payable days | 93.08 | 124.60 | 108.80 | 86.14 | 102.62 |
| Valuation Parameters | |||||
| PER(x) | 23.84 | 26.76 | 15.93 | 16.03 | 8.33 |
| PCE(x) | 16.07 | 19.64 | 11.24 | 12.30 | 7.30 |
| Price/Book(x) | 0.71 | 0.96 | 0.52 | 0.94 | 0.56 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.27 | 0.39 | 0.23 | 0.24 | 0.21 |
| EV/Core EBITDA(x) | 10.17 | 13.59 | 9.29 | 8.47 | 6.14 |
| EV/EBIT(x) | 12.01 | 15.96 | 10.94 | 9.86 | 6.67 |
| EV/CE(x) | 0.75 | 0.95 | 0.63 | 0.93 | 0.61 |
| M Cap / Sales | 0.20 | 0.32 | 0.14 | 0.21 | 0.16 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 19.19 | -5.09 | -14.98 | 41.43 | 16.10 |
| Core EBITDA Growth(%) | 11.34 | 9.24 | -25.68 | 20.55 | 17.58 |
| EBIT Growth(%) | 10.78 | 9.48 | -26.48 | 12.37 | 19.02 |
| PAT Growth(%) | -14.09 | 24.20 | -42.47 | 0.62 | 12.44 |
| EPS Growth(%) | -15.29 | 12.38 | -42.47 | -7.31 | 12.44 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.26 | 0.24 | 0.33 | 0.13 | 0.19 |
| Current Ratio(x) | 1.78 | 1.70 | 1.61 | 1.73 | 1.67 |
| Quick Ratio(x) | 1.48 | 1.49 | 1.44 | 1.62 | 1.53 |
| Interest Cover(x) | 2.31 | 2.22 | 3.10 | 5.93 | 4.40 |
| Total Debt/Mcap(x) | 0.36 | 0.25 | 0.63 | 0.13 | 0.33 |
Compare Financial Ratios of peers of AAREY DRUGS & PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AAREY DRUGS & PHARMACEUTICALS | ₹190.3 Cr | -7.7% | -29.3% | 8.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹430,513.0 Cr | -0.1% | 3.4% | -0.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹170,614.0 Cr | 1.6% | -2.5% | 8.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹128,245.0 Cr | 0.8% | -0.9% | 13.5% | Stock Analytics | |
| CIPLA | ₹122,555.0 Cr | 1.3% | -0.6% | 3.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,803.0 Cr | 1% | 3.7% | 2.7% | Stock Analytics | |
AAREY DRUGS & PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AAREY DRUGS & PHARMACEUTICALS | -7.7% |
-29.3% |
8.7% |
| SENSEX | -0.5% |
1% |
4.6% |
You may also like the below Video Courses
